|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M and Rabe KF: Advanced
non-small-cell lung cancer. N Engl J Med. 377:19992017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du L, Waqar SN and Morgensztern D:
Multimodality therapy for NSCLC. Cancer Treat Res. 170:151–163.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sgambato A, Casaluce F, Maione P and
Gridelli C: Targeted therapies in non-small cell lung cancer: A
focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer
Ther. 18:71–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arbour KC and Riely GJ: Systemic therapy
for locally advanced and metastatic non-small cell lung cancer: A
review. JAMA. 322:764–774. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Durrant DE, Das A, Dyer S, Tavallai S,
Dent P and Kukreja RC: Targeted inhibition of phosphoinositide
3-kinase/mammalian target of rapamycin sensitizes pancreatic cancer
cells to doxorubicin without exacerbating cardiac toxicity. Mol
Pharmacol. 88:512–523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amawi H, Sim HM, Tiwari AK, Ambudkar SV
and Shukla S: ABC transporter-mediated multidrug-resistant cancer.
Adv Exp Med Biol. 1141:549–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Babichev Y, Kabaroff L, Datti A, Uehling
D, Isaac M, Al-Awar R, Prakesch M, Sun RX, Boutros PC, Venier R, et
al: PI3K/AKT/mTOR inhibition in combination with doxorubicin is an
effective therapy for leiomyosarcoma. J Transl Med. 14:672016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zucali PA, Perrino M, De Vincenzo F,
Giordano L, Cordua N, D'Antonio F and Santoro A: A phase II study
of the combination of gemcitabine and imatinib mesylate in
pemetrexed-pretreated patients with malignant pleural mesothelioma.
Lung Cancer. 142:132–137. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao W, Yang Q, Yuan Z, Li H, Wang W, Xiao
X, Wang Z, Liang L, Zhou P, Liu J, et al: Gemcitabine inhibits
cisplatin resistance in cisplatin-resistant A549 cells by
upregulating trx-interacting protein and inducing cell cycle
arrest. Biochem Biophys Res Commun. 524:549–554. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou M, Zheng J, Bi J, Wu X, Lyu J and Gao
K: Synergistic inhibition of colon cancer cell growth by a
combination of atorvastatin and phloretin. Oncol Lett.
15:1985–1992. 2018.PubMed/NCBI
|
|
17
|
Gasparri ML, Besharat ZM, Farooqi AA,
Khalid S, Taghavi K, Besharat RA, Sabato C, Papadia A, Panici PB,
Mueller MD and Ferretti E: MiRNAs and their interplay with
PI3K/AKT/mTOR pathway in ovarian cancer cells: A potential role in
platinum resistance. J Cancer Res Clin Oncol. 144:2313–2318. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bahrami A, Khazaei M, Hasanzadeh M,
ShahidSales S, Joudi Mashhad M, Farazestanian M, Sadeghnia HR,
Rezayi M, Maftouh M, Hassanian SM and Avan A: Therapeutic potential
of targeting PI3K/AKT pathway in treatment of colorectal cancer:
Rational and progress. J Cell Biochem. 119:2460–2469. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gohr K, Hamacher A, Engelke LH and Kassack
MU: Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in
the triple negative breast cancer cell line HCC38. BMC Cancer.
17:7112017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moon du G, Lee SE, Oh MM, Lee SC, Jeong
SJ, Hong SK, Yoon CY, Byun SS, Park HS and Cheon J: NVP-BEZ235, a
dual PI3K/mTOR inhibitor synergistically potentiates the antitumor
effects of cisplatin in bladder cancer cells. Int J Oncol.
45:1027–1035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Nie J, Ma X, Wei Y, Peng Y and Wei
X: Targeting PI3K in cancer: Mechanisms and advances in clinical
trials. Mol Cancer. 18:262019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ceballos MP, Rigalli JP, Ceré LI, Semeniuk
M, Catania VA and Ruiz ML: ABC transporters: Regulation and
association with multidrug resistance in hepatocellular carcinoma
and colorectal carcinoma. Curr Med Chem. 26:1224–1250. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen YL, Yang TY, Chen KC, Wu CL, Hsu SL
and Hsueh CM: Hypoxia can impair doxorubicin resistance of
non-small cell lung cancer cells by inhibiting MRP1 and P-gp
expression and boosting the chemosensitizing effects of MRP1 and
P-gp blockers. Cell Oncol (Dordr). 39:411–433. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ke B, Wei T, Huang Y, Gong Y, Wu G, Liu J,
Chen X and Shi L: Interleukin-7 resensitizes non-small-cell lung
cancer to cisplatin via inhibition of ABCG2. Mediators Inflamm.
2019:72414182019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang Z, Chen W, Yuan Z, Liu X and Jiang H:
LncRNA-MALAT1 contributes to the cisplatin-resistance of lung
cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed
Pharmacother. 101:536–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao Z, Liang N, Yang H and Li S: Visfatin
mediates doxorubicin resistance in human non-small-cell lung cancer
via Akt-mediated up-regulation of ABCC1. Cell Prolif.
50:e123662017. View Article : Google Scholar
|
|
28
|
Leung E, Kim JE, Rewcastle GW, Finlay GJ
and Baguley BC: Comparison of the effects of the PI3K/mTOR
inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast
cancer cells. Cancer Biol Ther. 11:938–946. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng L, Jiang L, Lin XH, Tseng KF, Liu Y,
Zhang X, Dong RH, Lu ZG and Wang XJ: The PI3K/mTOR dual inhibitor
BEZ235 suppresses proliferation and migration and reverses
multidrug resistance in acute myeloid leukemia. Acta Pharmacol Sin.
38:382–391. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wise-Draper TM, Moorthy G, Salkeni MA,
Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O,
Fathallah H, et al: A phase Ib study of the dual PI3K/mTOR
inhibitor dactolisib (BEZ235) combined with everolimus in patients
with advanced solid malignancies. Target Oncol. 12:323–332. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia A, Li H, Li R, Lu L and Wu X:
Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP
cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and
downregulation of ERCC1 expression. Oncol Rep. 40:2353–2362.
2018.PubMed/NCBI
|
|
32
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie J, Xu W, Wu Y, Niu B and Zhang X:
Macroporous organosilicon nanocomposites co-deliver Bcl2-converting
peptide and chemotherapeutic agent for synergistic treatment
against multidrug resistant cancer. Cancer Lett. 469:340–354. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Besse B, Garrido P, Cortot AB, Johnson M,
Murakami H, Gazzah A, Gil M and Bennouna J: Efficacy and safety of
necitumumab and pembrolizumab combination therapy in patients with
Stage IV non-small cell lung cancer. Lung Cancer. 142:63–69. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xin P, Li C, Zheng Y, Peng Q, Xiao H,
Huang Y and Zhu X: Efficacy of the dual PI3K and mTOR inhibitor
NVP-BEZ235 in combination with imatinib mesylate against chronic
myelogenous leukemia cell lines. Drug Des Devel Ther. 11:1115–1126.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou M, Shen S, Zhao X and Gong X:
Luteoloside induces G0/G1 arrest and pro-death autophagy through
the ROS-mediated AKT/mTOR/p70S6K signalling pathway in human
non-small cell lung cancer cell lines. Biochem Biophys Res Commun.
494:263–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen D, Wang Y, Niu H and Liu C:
Gambogenic acid exerts anticancer effects in
cisplatinresistantnonsmall cell lung cancer cells. Mol Med Rep.
21:1267–1275. 2020.PubMed/NCBI
|
|
38
|
Tavares MR, Pavan IC, Amaral CL,
Meneguello L, Luchessi AD and Simabuco FM: The S6K protein family
in health and disease. Life Sci. 131:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin G, Gai R, Chen Z, Wang Y, Liao S, Dong
R, Zhu H, Gu Y, He Q and Yang B: The dual PI3K/mTOR inhibitor
NVP-BEZ235 prevents epithelial-mesenchymal transition induced by
hypoxia and TGF-β1. Eur J Pharmacol. 729:45–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
